Tivic Health Systems Inc. has announced the expansion of its patent portfolio with a new filing for a Vagus Nerve Stimulation (VNS) System. The recently filed patent, No. 63,801,058, aims to enhance the efficacy of non-invasive VNS technology by focusing on the personalization of stimulation parameters and electrode positioning. This development is expected to advance the state-of-the-art in vagus nerve interventions, offering improved therapeutic effects. Tivic's Chief Scientific Officer, Blake Gurfein, emphasized the company's commitment to building a defensible position for its next-generation VNS technology. CEO Jennifer Ernst highlighted the importance of protecting the company's intellectual property as they continue to advance their VNS program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.